Central Nervous System Lymphoma
43
15
21
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.7%
2 terminated out of 43 trials
86.7%
+0.2% vs benchmark
5%
2 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (43)
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Acalabrutinib in CNSL
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
DALY II USA/ MB-CART2019.1 for DLBCL
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma